tiprankstipranks
Trending News
More News >
CalciMedica (CALC)
NASDAQ:CALC
US Market
Advertisement

CalciMedica (CALC) AI Stock Analysis

Compare
274 Followers

Top Page

CALC

CalciMedica

(NASDAQ:CALC)

Rating:39Underperform
Price Target:
CalciMedica's low stock score reflects its financial challenges, including zero revenue and negative cash flows. However, technical indicators suggest the stock is currently oversold, providing a potential entry point for risk-tolerant investors. The promising results from the Auxora trial offer a positive outlook, potentially improving future financial performance.
Positive Factors
Clinical Trials
Auxora advances in AKI with a positive read-through demonstrating a 62.7% relative reduction in mortality at day 30, which persisted through day 60, for patients treated with Auxora versus placebo.
Market Opportunity
With over 1 million patients in the AKI Auxora target market, there is anticipation of a significant market opportunity exceeding $10 billion.
Negative Factors
Financial Performance
CalciMedica announced 1Q25 financial results, posting EPS of ($0.36), compared to our estimate of ($0.33) and consensus of ($0.31).

CalciMedica (CALC) vs. SPDR S&P 500 ETF (SPY)

CalciMedica Business Overview & Revenue Model

Company DescriptionCalciMedica (CALC) is a biotechnology company focused on the development of therapies to treat inflammatory and autoimmune diseases. The company specializes in targeting calcium release-activated calcium (CRAC) channels, which play a crucial role in the activation of immune cells. CalciMedica's lead product candidate is Auxora, a CRAC channel inhibitor designed to treat severe inflammatory diseases such as acute pancreatitis and COVID-19 pneumonia.
How the Company Makes MoneyCalciMedica generates revenue primarily through the development and commercialization of its pharmaceutical products. The company may earn money through partnerships, collaborations, and licensing agreements with other pharmaceutical and biotechnology companies. These arrangements often involve upfront payments, milestone payments, and royalties on sales. Additionally, CalciMedica may receive funding from government grants or research institutions to support its clinical trials and drug development programs. The success of its lead product candidate, Auxora, in clinical trials and its eventual approval and commercialization would be a significant source of revenue for the company.

CalciMedica Financial Statement Overview

Summary
CalciMedica faces significant financial challenges, primarily due to the absence of revenue and persistent operational losses. The reduction in debt and consistent asset base are positive signs, but the shrinking equity and negative cash flows highlight the need for strategic financial and operational improvements.
Income Statement
10
Very Negative
CalciMedica has consistently reported zero revenue over the years, reflecting challenges in commercializing its biotechnology pipeline. Despite some reduction in net losses, the company continues to operate with substantial negative EBIT and EBITDA margins, indicating persistent operational inefficiencies.
Balance Sheet
30
Negative
The balance sheet shows a positive trend in reducing debt, with the company having zero total debt in recent years. However, the equity has significantly diminished from 2019 to 2024, impacting the equity ratio negatively. The company maintains a stable asset base, which is positive, but the shrinking equity indicates potential financial instability.
Cash Flow
20
Very Negative
Free cash flow remains negative, and the operating cash flow is consistently negative as well, reflecting cash burn typical for early-stage biotech firms. Despite improvements in free cash flow growth from 2023 to 2024, the overall cash flow position highlights the need for efficient cash management and potential additional financing.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue0.000.000.000.000.00
Gross Profit0.00-58.00K-52.00K-519.00K-395.00K
EBITDA-13.64M-34.19M-7.64M-35.30M-27.14M
Net Income-13.70M-34.36M-35.60M-35.82M-27.53M
Balance Sheet
Total Assets19.79M12.19M39.67M69.09M101.79M
Cash, Cash Equivalents and Short-Term Investments18.67M11.24M39.13M63.67M95.03M
Total Debt0.000.00203.00K0.000.00
Total Liabilities5.38M4.03M3.70M4.07M7.01M
Stockholders Equity14.41M8.16M35.97M65.02M94.79M
Cash Flow
Free Cash Flow-21.15M-25.81M-25.13M-31.99M-33.09M
Operating Cash Flow-21.15M-25.73M-22.88M-31.50M-32.06M
Investing Cash Flow-4.42M8.88M26.96M10.75M-42.56M
Financing Cash Flow27.97M20.90M-139.00K695.00K92.17M

CalciMedica Technical Analysis

Technical Analysis Sentiment
Positive
Last Price4.20
Price Trends
50DMA
1.95
Positive
100DMA
1.90
Positive
200DMA
2.54
Positive
Market Momentum
MACD
0.53
Negative
RSI
72.88
Negative
STOCH
89.92
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CALC, the sentiment is Positive. The current price of 4.2 is above the 20-day moving average (MA) of 2.24, above the 50-day MA of 1.95, and above the 200-day MA of 2.54, indicating a bullish trend. The MACD of 0.53 indicates Negative momentum. The RSI at 72.88 is Negative, neither overbought nor oversold. The STOCH value of 89.92 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CALC.

CalciMedica Risk Analysis

CalciMedica disclosed 71 risk factors in its most recent earnings report. CalciMedica reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

CalciMedica Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
61
Neutral
$26.12M-167.57%127.51%71.16%
54
Neutral
$83.29M-121.65%-0.71%-169.29%
53
Neutral
$49.78M-36.31%15.73%51.00%
52
Neutral
$7.62B0.05-63.03%2.44%16.33%0.31%
39
Underperform
$58.68M-134.15%95.48%
36
Underperform
$25.11M-39.78%84.17%
33
Underperform
$20.75M-112.99%57.93%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CALC
CalciMedica
3.69
-0.25
-6.35%
TENX
Tenax Therapeutics
6.11
2.72
80.24%
OVID
Ovid Therapeutics
0.69
-0.37
-34.91%
CMMB
Chemomab Therapeutics
1.09
-0.18
-14.17%
IPA
ImmunoPrecise Antibodies
2.31
1.45
168.60%
LGVN
Longeveron
1.69
-1.75
-50.87%

CalciMedica Corporate Events

Product-Related AnnouncementsBusiness Operations and Strategy
CalciMedica Highlights Auxora’s Potential in COVID-19 Treatment
Positive
Mar 4, 2025

On March 4, 2025, CalciMedica announced new data from a post-hoc analysis of the Phase 2 CARDEA trial, highlighting Auxora’s potential in reducing mortality among patients with severe COVID-19 pneumonia and acute kidney injury (AKI). The analysis revealed a 62.7% relative reduction in mortality for Auxora-treated patients compared to placebo, indicating a significant therapeutic benefit. This data underscores the potential of CRAC channel inhibition in treating AKI and supports ongoing clinical trials, which may enhance CalciMedica’s positioning in the biopharmaceutical industry.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 21, 2025